February 12, 2026. — Leads & Copy — Median Technologies and Tempus AI, Inc. have entered into a non-exclusive distribution agreement to bring Median’s eyonis® LCS, an AI-powered software for early lung cancer diagnosis, to U.S. imaging providers through Tempus AI’s Tempus Pixel platform.
The agreement will allow Tempus AI to distribute eyonis® LCS to U.S. imaging providers through the Tempus Pixel platform and support implementation, customer onboarding, and workflow integration.
Median Technologies, developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a provider of AI-enhanced and central imaging services for oncology drug developers, announced the agreement. Tempus AI (NASDAQ: TEM) is a technology company focused on using AI to advance precision medicine.
eyonis® LCS received FDA 510(k) clearance on February 9, 2026. It is an AI-based CADe/CADx Software as a Medical Device (SaMD) for lung cancer screening.
According to Median, eyonis® LCS is capable of detecting and characterizing lung cancer in low-dose CT scans (LDCT), with 93.3% sensitivity, 92.4% specificity, and 99.9% Negative Predictive Value (NPV) (manufacturer values calculated on a lung cancer screening reference population). The company says it helps clinicians identify suspicious findings earlier and improve the efficiency and consistency of lung cancer screening programs.
Tempus Pixel1, is an FDA-cleared, CE-marked AI-enabled solution that offers advanced analysis, tools, and automated reporting from radiology images to help providers accurately track and quantify lesions. It aims to aid providers in making informed diagnostic and disease management decisions.
Fredrik Brag, CEO and Founder of Median Technologies, noted that activating the distribution collaboration with Tempus AI is a decisive step in bringing eyonis® LCS to patients at a national scale.
Razik Yousfi, Tempus SVP & GM, AI Products, said the collaboration with Median Technologies is about improving the standard of care and preventing avoidable deaths through better screening access.
Revenues generated from the use of eyonis® LCS will be shared between the parties in accordance with the commercial terms of the partnership. The collaboration builds on the existing NT-APC 1508 reimbursement pathway ($601–$700) and targets the 14.5 million Americans eligible for lung cancer screening.
Median anticipates obtaining CE marking in Q2 2026 for eyonis® LCS. Under the executed distribution agreement, Tempus AI would support the commercial rollout of eyonis® LCS across Europe.
Median Technologies announced the signature of the non-exclusive distribution agreement on December 8, 2025, without disclosing the partner’s identity.
Median Technologies, based in France with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT) and is eligible for the French SME equity savings plan scheme (PEA-PME).
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.
1Tempus Pixel is manufactured and registered under Arterys Inc., a wholly owned subsidiary of Tempus, for both FDA and CE Mark purposes.
Source: Median Technologies
